PMID- 27693214
OWN - NLM
STAT- MEDLINE
DCOM- 20171207
LR  - 20220321
IS  - 1879-0542 (Electronic)
IS  - 0165-2478 (Linking)
VI  - 181
DP  - 2017 Jan
TI  - Identification of the impact on T- and B- cell epitopes of human papillomavirus 
      type-16 E6 and E7 variant in Southwest China.
PG  - 26-30
LID - S0165-2478(16)30187-0 [pii]
LID - 10.1016/j.imlet.2016.09.013 [doi]
AB  - Cervical cancers almost are infected by human papillmavirus (HPV), encoding E6 
      and E7 oncoproteins which are regard as ideal targets on the mechanism of this 
      disease and development of vaccines. HLA (human leukocyte antigen) participates 
      in the local immune response to prevent tumor invasion and progression. But due 
      to highly polymorphism of HLA, prediction shows its importance in this study. 
      More effective immunoinformatics was used for predicting epitopes from HPV-16 E6 
      and E7, including T- and B-cell epitopes. Eight substitutions are detected. 
      Specifically speaking, for HLA-I, HLA-A*33:03 (26), HLA-B*13:01 (14), HLA-C*03:02 
      (5) for E6 and HLA-A*02:01 (6), HLA-B*40:01 (5), HLA-C*03:04 (4) for E7 are most 
      frequency. Epitope (41-48)EVYDFAFR for HLA-A*33:03 (0.1) for E6 has best binding 
      affinity, as well as HLA*02:01 and HLA-B*40:01 (0.2) for E7. The mutations of 
      D25E and L83V of E6 and N29S of E7 produce new epitopes, and the percentile 
      values change with them. For HLA-II, seventeen epitopes in the reference at 
      percentile value from 0.22 to 4.76, while in variant from 0.22 to 4.96. For the 
      B-cell epitopes, three most potent epitopes for E6 were listed, and N29S lead the 
      growth of score from 0.81 to 0.83. In summary, E6(40-55)REVYDFAFRDLCIVYR and 
      E7(11-22)YMLDLQPETTDL are the important regions, containing the majority of 
      predicted epitopes. E6 72-83 for HLA-A*02:01 and E6 74-84 for HLA-B*15:02 maybe 
      are the new direct for therapeutic vaccine aimed at L83V variants. HLA-DRB1*15:02 
      is better binder with T cell in our HLA class II. It is a systematic, detail 
      recognition for T- and B-cell epitopes of HPV-16 E6 and E7 from Southwest China, 
      which may be helpful to design vaccines specifically for women in Southwest China 
      and testing methods specifically for this region. The results of our study may 
      contribute to future researches on vaccines improvement, or screening methods for 
      a particular population.
CI  - Copyright (c) 2016 European Federation of Immunological Societies. Published by 
      Elsevier B.V. All rights reserved.
FAU - Chenzhang, Yuwei
AU  - Chenzhang Y
AD  - Key Laboratory of Bio-Resources and Eco-Environment, Ministry of Education, 
      Institute of Medical Genetics, College of Life Science, Sichuan University, 
      China; Bio-Resource Research and Utilization Joint Key Laboratory of Sichuan and 
      Chongqing, Sichuan and Chongqing, China.
FAU - Wen, Qiang
AU  - Wen Q
AD  - Key Laboratory of Bio-Resources and Eco-Environment, Ministry of Education, 
      Institute of Medical Genetics, College of Life Science, Sichuan University, 
      China; Bio-Resource Research and Utilization Joint Key Laboratory of Sichuan and 
      Chongqing, Sichuan and Chongqing, China.
FAU - Ding, Xianping
AU  - Ding X
AD  - Key Laboratory of Bio-Resources and Eco-Environment, Ministry of Education, 
      Institute of Medical Genetics, College of Life Science, Sichuan University, 
      China; Bio-Resource Research and Utilization Joint Key Laboratory of Sichuan and 
      Chongqing, Sichuan and Chongqing, China. Electronic address: 
      brainding@scu.edu.cn.
FAU - Cao, Man
AU  - Cao M
AD  - Key Laboratory of Bio-Resources and Eco-Environment, Ministry of Education, 
      Institute of Medical Genetics, College of Life Science, Sichuan University, 
      China; Bio-Resource Research and Utilization Joint Key Laboratory of Sichuan and 
      Chongqing, Sichuan and Chongqing, China.
FAU - Chen, Zuyi
AU  - Chen Z
AD  - Key Laboratory of Bio-Resources and Eco-Environment, Ministry of Education, 
      Institute of Medical Genetics, College of Life Science, Sichuan University, 
      China; Bio-Resource Research and Utilization Joint Key Laboratory of Sichuan and 
      Chongqing, Sichuan and Chongqing, China.
FAU - Mu, Xuemei
AU  - Mu X
AD  - Key Laboratory of Bio-Resources and Eco-Environment, Ministry of Education, 
      Institute of Medical Genetics, College of Life Science, Sichuan University, 
      China; Bio-Resource Research and Utilization Joint Key Laboratory of Sichuan and 
      Chongqing, Sichuan and Chongqing, China.
FAU - Wang, Tao
AU  - Wang T
AD  - Key Laboratory of Bio-Resources and Eco-Environment, Ministry of Education, 
      Institute of Medical Genetics, College of Life Science, Sichuan University, 
      China; Bio-Resource Research and Utilization Joint Key Laboratory of Sichuan and 
      Chongqing, Sichuan and Chongqing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160928
PL  - Netherlands
TA  - Immunol Lett
JT  - Immunology letters
JID - 7910006
RN  - 0 (E6 protein, Human papillomavirus type 16)
RN  - 0 (Epitopes, B-Lymphocyte)
RN  - 0 (Epitopes, T-Lymphocyte)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Histocompatibility Antigens Class II)
RN  - 0 (Oncogene Proteins, Viral)
RN  - 0 (Papillomavirus E7 Proteins)
RN  - 0 (Repressor Proteins)
RN  - 0 (oncogene protein E7, Human papillomavirus type 16)
SB  - IM
MH  - Alleles
MH  - China
MH  - DNA Mutational Analysis
MH  - Epitopes, B-Lymphocyte/chemistry/*immunology
MH  - Epitopes, T-Lymphocyte/chemistry/*immunology
MH  - *Genetic Variation
MH  - Histocompatibility Antigens Class I/genetics/immunology
MH  - Histocompatibility Antigens Class II/genetics/immunology
MH  - Humans
MH  - Mutation
MH  - Oncogene Proteins, Viral/chemistry/*genetics/*immunology
MH  - Papillomavirus E7 Proteins/chemistry/*genetics/*immunology
MH  - Papillomavirus Infections/*immunology/virology
MH  - Phylogeny
MH  - Repressor Proteins/chemistry/*genetics/*immunology
OTO - NOTNLM
OT  - Cervical cancer
OT  - Human leukocyte antigen
OT  - Human papillomavirus-16 E6/E7
OT  - Southwest China
OT  - T- and B-cell epitopes prediction
EDAT- 2016/10/04 06:00
MHDA- 2017/12/08 06:00
CRDT- 2016/10/04 06:00
PHST- 2016/07/21 00:00 [received]
PHST- 2016/09/18 00:00 [revised]
PHST- 2016/09/26 00:00 [accepted]
PHST- 2016/10/04 06:00 [pubmed]
PHST- 2017/12/08 06:00 [medline]
PHST- 2016/10/04 06:00 [entrez]
AID - S0165-2478(16)30187-0 [pii]
AID - 10.1016/j.imlet.2016.09.013 [doi]
PST - ppublish
SO  - Immunol Lett. 2017 Jan;181:26-30. doi: 10.1016/j.imlet.2016.09.013. Epub 2016 Sep 
      28.